GlassScriptPhysician profile
Cornell M Cohen
NPI 1841204526
$8,026.57
in general payments reported to CMS, 2019-2025
36 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $733 · 2021: $1,438 · 2022: $1,445 · 2023: $1,242 · 2024: $1,678 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.29 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,028.13 | 2020-2024 | Cardiomems, Mitraclip, Jot Dx |
| Pfizer INC. | $651.21 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $630.35 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $602.59 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $542.65 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $540.67 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.75 | 2019-2024 | Jardiance |
| Amgen INC. | $469.66 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $435.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $361.08 | 2019-2024 | Xarelto |
| Cvrx, INC. | $349.48 | 2022-2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $224.17 | 2023-2024 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $193.25 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $185.72 | 2019-2022 | |
| Boston Scientific Corporation | $132.96 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornell Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.